Abstract

ObjectiveTo study the macrostructural and microstructural MRI correlates of brain astrocytosis, measured with 11C-deuterium-L-deprenyl (11C-DED)–PET, in familial autosomal-dominant Alzheimer disease (ADAD).MethodsThe total sample (n = 31) comprised ADAD mutation carriers (n = 10 presymptomatic, 39.2 ± 10.6 years old; n = 3 symptomatic, 55.5 ± 2.0 years old) and noncarriers (n = 18, 44.0 ± 13.7 years old) belonging to families with mutations in either the presenilin-1 or amyloid precursor protein genes. All participants underwent structural and diffusion MRI and neuropsychological assessment, and 20 participants (6 presymptomatic and 3 symptomatic mutation carriers and 11 noncarriers) also underwent 11C-DED-PET.ResultsVertex-wise interaction analyses revealed a differential relationship between carriers and noncarriers in the association between 11C-DED binding and estimated years to onset (EYO) and between cortical mean diffusivity (MD) and EYO. These differences were due to higher 11C-DED binding in presymptomatic carriers, with lower binding in symptomatic carriers compared to noncarriers, and to lower cortical MD in presymptomatic carriers, with higher MD in symptomatic carriers compared to noncarriers. Using a vertex-wise local correlation approach, 11C-DED binding was negatively correlated with cortical MD and positively correlated with cortical thickness.ConclusionsOur proof-of-concept study is the first to show that microstructural and macrostructural changes can reflect underlying neuroinflammatory mechanisms in early stages of Alzheimer disease (AD). The findings support a role for neuroinflammation in AD pathogenesis, with potential implications for the correct interpretation of neuroimaging biomarkers as surrogate endpoints in clinical trials.

Highlights

  • The total sample (n = 31) comprised autosomal-dominant Alzheimer disease (ADAD) mutation carriers (n = 10 presymptomatic, 39.2 ± 10.6 years old; n = 3 symptomatic, 55.5 ± 2.0 years old) and noncarriers (n = 18, 44.0 ± 13.7 years old) belonging to families with mutations in either the presenilin-1 or amyloid precursor protein genes

  • The findings support a role for neuroinflammation in AD pathogenesis, with potential implications for the correct interpretation of neuroimaging biomarkers as surrogate endpoints in clinical trials

  • Using structural and diffusion MRI, we recently proposed a model of gray matter (GM) changes in sporadic AD,[13,14,15,16] in which an early presymptomatic phase of decreased cortical mean diffusivity (MD) and increased cortical thickness (CTh) is followed by increased cortical MD and decreased CTh at symptomatic stages

Read more

Summary

Methods

Symptom onset in mutation carriers is defined as the time at which the first clinically relevant cognitive symptoms appeared, as either experienced by the patient or noticed by near relatives. In this cohort, the average age at onset was earliest (36 ± 2 years) in PSEN1 Ile143Thr mutation carriers, while it was similar in carriers of the other 3 mutations: PSEN1 His163Tyr (52 ± 7 years), APPswe KM670/671NL (54 ± 5 years), and APParc Glu693Gly (56 ± 3 years).[19] The average age at onset in each family was calculated from medical records for disease onset in individuals from that family (5, 9, 24, and 12 individuals for the 4 mutation types, respectively). We only use it in the interaction analyses to have the participants in the same temporal dimension

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call